SEC Form 4 · accession 0001209191-17-041626
Evofem Biosciences, Inc. · EVFM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Maria Feldman
Officer — VP, Clinical Research
Period of report
Jun 22, 2017
Accepted (ET)
Jun 23, 2017 · 4:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001618835
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $2.27 | Jun 22, 2017 | A | 140,000 | A | — | Jun 22, 2027 | Common Stock | 140,000 | 140,000 | D |
Explanation of responses
- F1Option shares vest and become exercisable in twenty-four (24) successive equal monthly installments measured from June 22, 2017.